Overview

Update
IPO / Stock
Went Public on Feb 2, 2007 / OTCMKTS:AVXL
Total Equity Funding
$2.6M in 1 Round
Headquarters:
New York, NY
Description:
Anavex is a biopharmaceutical company developing drugs for the treatment of cancer and neurological diseases.
Founders:
Categories:
Biopharma, Therapeutics, Biotechnology
Website:
http://anavex.com
Social:

Company Details

Update

Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term.

Funding Rounds (2) - $12.6M

Update
DateAmount / RoundValuationLead InvestorInvestors
Mar, 2014$10M / Post Ipo Debt0
Jul, 2013$2.6M / Private Equity0

Current Team (2)

Update

Offices/Locations (1)

Update
  • Office

    51 West 52nd Street

    7th floor

    New York, NY NY 10019

    USA

Past Team (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Images

Add Videos